Get the Stockscreener App
1.98
1.00%
-0.02
After Hours:
1.95
-0.03
-1.52%
Prokidney Corp stock is traded at $1.98, with a volume of 515.96K.
It is down -1.00% in the last 24 hours and down -15.02% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$2.00
Open:
$2.01
24h Volume:
515.96K
Relative Volume:
0.43
Market Cap:
$280.26M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-3.4737
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+14.45%
1M Performance:
-15.02%
6M Performance:
-11.61%
1Y Performance:
+28.57%
1-Day Range:
$1.91
$2.02
1-Week Range:
$1.74
$2.12
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.98 | 283.09M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
Is ProKidney Corp. stock a top performer YTDInflation Watch & Free Reliable Trade Execution Plans - mfd.ru
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - 富途牛牛
Revenue Check: Will ProKidney Corp benefit from geopolitical trendsBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
Will ProKidney Corp. stock keep outperforming rivalsJuly 2025 Price Swings & Fast Moving Market Watchlists - mfd.ru
Layoff Watch: Does ProKidney Corp offer margin of safety2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
ProKidney Corp Explodes Into the Spotlight: Breakthrough Stock or Overhyped Trap? - AD HOC NEWS
HC Wainwright Forecasts ProKidney FY2030 Earnings - MarketBeat
Growth Value: Will CVCO benefit from sector rotationJuly 2025 WrapUp & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Is ProKidney Corp stock undervalued right nowMarket Growth Review & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
ProKidney Shares Soar After Citi Lifts Price Target to $9 - MSN
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating - TipRanks
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans - TipRanks
ProKidney CorpTopline data readout of surrogate endpoint expected Q2 2027 - marketscreener.com
Prokidney CorpTopline Data Readout Of Surrogate Endpoint Expected Q2 2027 - TradingView
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) - Seeking Alpha
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of "Hold" from Analysts - MarketBeat
Can ProKidney Corp. continue delivering strong returns2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
Macro Review: Can CBTJ expand its profit margins2025 Volatility Report & Consistent Growth Equity Picks - baoquankhu1.vn
Aug Action: Can ProKidney Corp be the next market leaderTreasury Yields & Stock Portfolio Risk Management - baoquankhu1.vn
Why is ProKidney Corp. stock going downWeekly Trade Report & Fast Gain Stock Tips - mfd.ru
Ideas Watch: Should I buy ProKidney Corp stock nowTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Profit Review: Does ProKidney Corp outperform in volatile marketsTrade Entry Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Investment Review: Does ProKidney Corp offer margin of safety2025 Support & Resistance & Risk Controlled Daily Trade Plans - baoquankhu1.vn
PROKProKidney Latest Stock News & Market Updates - Stock Titan
ProKidney (NASDAQ:PROK) Stock Price Down 5.5%What's Next? - MarketBeat
Risk Recap: Why is ProKidney Corp stock going downPortfolio Update Report & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Bear Alert: Why is ProKidney Corp stock going downCPI Data & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
H.C. Wainwright Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
PROK: Pivotal phase III trial of rilparencel for advanced CKD targets Q2 2027 readout, with strong phase II results - TradingView
Recap Report: What is the cash position of ProKidney CorpBuy Signal & Free High Return Stock Watch Alerts - baoquankhu1.vn
ProKidney Advances Rilparencel Program and Manufacturing Expansion - TipRanks
ProKidney Corp Updates on Rilparencel and Phase 3 Trials - TradingView
Will ProKidney Corp. stock maintain momentum in 2025Bull Run & Consistent Return Investment Signals - ulpravda.ru
Why ProKidney Corp. stock could benefit from AI revolutionJuly 2025 Outlook & Risk Managed Investment Strategies - Улправда
Earnings Update: How interest rate cuts could boost ProKidney Corp. stockJuly 2025 Levels & Community Driven Trade Alerts - Улправда
Is ProKidney Corp. stock attractive for passive investorsMarket Movement Recap & Reliable Intraday Trade Alerts - Улправда
Retail Trends: Why ProKidney Corp. stock could benefit from AI revolutionPortfolio Gains Summary & Fast Gain Stock Tips - Улправда
Is ProKidney Corp. stock supported by strong fundamentalsEarnings Growth Summary & Weekly Market Pulse Alerts - Улправда
3 Penny Stocks With Market Caps Under $700M - simplywall.st
Is ProKidney Corp. stock a buy on dipsDouble Top/Bottom Patterns & Rapid Profit Growth - ulpravda.ru
ProKidney (NASDAQ:PROK) Trading 6.9% HigherTime to Buy? - MarketBeat
ProKidney Corp. CEO Bruce Culleton to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Hold" by Analysts - MarketBeat
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
ProKidney (NASDAQ:PROK) Shares Down 7.3%Should You Sell? - MarketBeat
B of A Securities Downgrades ProKidney (PROK) - MSN
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney Corp. (PROK) positioned to redefine chronic kidney disease treatment, believes HC Wainwright - MSN
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright - Yahoo Finance
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):